Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression

Epilepsy and Behavior

Volumn 28, Issue 2, 2013, Pages 243-248

  Zhang, XiChun ^a   Jakubowski, Moshe ^a   Buettner, Catherine ^a   Kainz, Vanessa ^a   Gold, Michael ^b   Burstein, Rami ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Epilepsy; Headache; Migraine; Pain; Trigeminal

Indexed keywords

POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; RETIGABINE; ANTICONVULSIVE AGENT; CARBAMIC ACID DERIVATIVE; PHENYLENEDIAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; HEADACHE; MALE; NONHUMAN; PAIN RECEPTOR; RAT; SEIZURE; ACTION POTENTIAL; ANIMAL; CYTOLOGY; DRUG ADMINISTRATION; DRUG EFFECTS; PAIN MEASUREMENT; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SPREADING CORTICAL DEPRESSION; STIMULATION; TIME; TRIGEMINUS GANGLION;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; CARBAMATES; CORTICAL SPREADING DEPRESSION; DRUG ADMINISTRATION SCHEDULE; MALE; NOCICEPTORS; PAIN MEASUREMENT; PHENYLENEDIAMINES; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; STIMULATION, CHEMICAL; TIME FACTORS; TRIGEMINAL GANGLION;

EID: 84879795907     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.02.029     Document Type: Article

References (53)

1. Aurora S.K., Cao Y., Bowyer S.M., Welch K.M. The occipital cortex is hyperexcitable in migraine: experimental evidence. Headache 1999, 39:469-476.
2. Leao A. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944, 7:359-390.
3. Leao A.A. Spreading depression. Funct Neurol 1986, 1:363-366.
4. Lauritzen M., Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984, 107:447-461.
5. Cao Y., Welch K.M., Aurora S., Vikingstad E.M. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999, 56:548-554.
6. Hadjikhani N., Sanchez Del Rio M., Wu O., et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001, 98:4687-4692.
7. Olesen J., Burstein R., Ashina M., Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009, 8:679-690.
8. Zhang X.C., Levy D., Noseda R., Kainz V., Jakubowski M., Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications to migraine with aura. J Neurosci 2010, 30:8807-8814.
9. Zhang X., Levy D., Kainz V., Noseda R., Jakubowski M., Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 2011, 69:855-865.
10. Wickenden A.D., Yu W., Zou A., Jegla T., Wagoner P.K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000, 58:591-600.
11. Tatulian L., Delmas P., Abogadie F.C., Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001, 21:5535-5545.
12. Main M.J., Cryan J.E., Dupere J.R., Cox B., Clare J.J., Burbidge S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000, 58:253-262.
13. Camerino D.C., Tricarico D., Desaphy J.F. Ion channel pharmacology. Neurotherapeutics 2007, 4:184-198.
14. Welch K.M., Lewis D. Migraine and epilepsy. Neurol Clin 1997, 15:107-114.
15. Belcastro V., Striano P., Kasteleijn-Nolst Trenite D.G., Villa M.P., Parisi P. Migralepsy, hemicrania epileptica, post-ictal headache and "ictal epileptic headache": a proposal for terminology and classification revision. J Headache Pain 2011, 12:289-294.
16. Tellez-Zenteno J.F., Matijevic S., Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia 2005, 46:1955-1962.
17. Haut S.R., Bigal M.E., Lipton R.B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006, 5:148-157.
18. Koch U.R., Musshoff U., Pannek H.W., et al. Intrinsic excitability, synaptic potentials, and short-term plasticity in human epileptic neocortex. J Neurosci Res 2005, 80:715-726.
19. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature 1999, 399:A15-A22.
20. Aurora S.K., Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 2007, 27:1442-1453.
21. Coppola G., Pierelli F., Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine?. Cephalalgia 2007, 27:1427-1439.
22. McCleskey E.W., Gold M.S. Ion channels of nociception. Annu Rev Physiol 1999, 61:835-856.
23. Marrion N.V. Control of M-current. Annu Rev Physiol 1997, 59:483-504.
24. Passmore G.M., Selyanko A.A., Mistry M., et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003, 23:7227-7236.
25. Strassman A.M., Raymond S.A., Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
26. Levy D., Burstein R., Strassman A.M. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005, 58:698-705.
27. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994, 117:199-210.
28. Ottman R., Lipton R.B. Is the comorbidity of epilepsy and migraine due to a shared genetic susceptibility?. Neurology 1996, 47:918-924.
29. Wang H.S., Pan Z., Shi W., et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998, 282:1890-1893.
30. Harriott A.M., Gold M.S. Electrophysiological properties of dural afferents in the absence and presence of inflammatory mediators. J Neurophysiol 2009, 101:3126-3134.
31. Porter R.J., Partiot A., Sachdeo R., Nohria V., Alves W.M. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
32. Ferron G.M., Paul J., Fruncillo R., et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002, 42:175-182.
33. Large C.H., Sokal D.M., Nehlig A., et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia 2012, 53:425-436.
34. Schulze-Bonhage A., Kurth C., Carius A., Steinhoff B.J., Mayer T. Seizure anticipation by patients with focal and generalized epilepsy: a multicentre assessment of premonitory symptoms. Epilepsy Res 2006, 70:83-88.
35. Lee S.A., No Y.J. Perceived self-control of seizures in patients with uncontrolled partial epilepsy. Seizure 2005, 14:100-105.
36. Vaughn A.H., Gold M.S. Ionic mechanisms underlying inflammatory mediator-induced sensitization of dural afferents. J Neurosci 2010, 30:7878-7888.
37. Saganich M.J., Machado E., Rudy B. Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 2001, 21:4609-4624.
38. Herreras O., Largo C., Ibarz J.M., Somjen G.G., Martin del Rio R. Role of neuronal synchronizing mechanisms in the propagation of spreading depression in the in vivo hippocampus. J Neurosci 1994, 14:7087-7098.
39. Herreras O., Somjen G.G. Propagation of spreading depression among dendrites and somata of the same cell population. Brain Res 1993, 610:276-282.
40. Sugaya E., Takato M., Noda Y. Neuronal and glial activity during spreading depression in cerebral cortex of cat. J Neurophysiol 1975, 38:822-841.
41. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
42. Freitag F.G., Collins S.D., Carlson H.A., et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
43. Loder E., Burch R., Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012, 52:930-945.
44. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol Life Sci 2007, 64:2090-2103.
45. Rho J.M., Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 1999, 40:1471-1483.
46. Johannessen C.U. Mechanisms of action of valproate: a commentary. Neurochem Int 2000, 37:103-110.
47. McLean M.J., Bukhari A.A., Wamil A.W. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000, 41(Suppl. 1):S21-S24.
48. Czapinski P., Blaszczyk B., Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005, 5:3-14.
49. Taverna S., Sancini G., Mantegazza M., Franceschetti S., Avanzini G. Inhibition of transient and persistent Na+current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999, 288:960-968.
50. Simeone T.A. Mechanisms of antiepileptic drug action. Epilepsy: mechanisms, models, and translational perspectives 2010, 123-141. CRC Press. J.M. Rho, R. Sankar, C.E. Stafstrom (Eds.).
51. Simeone T.A., Wilcox K.S., White H.S. cAMP-dependent protein kinase A activity modulates topiramate potentiation of GABA(A) receptors. Epilepsy Res 2011, 96:176-179.
52. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997, 336:243-249.
53. van Rijn C.M., Willems-van Bree E. Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol 2003, 464:95-100.